Cargando…
Histone Deacetylase Inhibitors and Diabetic Kidney Disease
Despite recent clinical trial advances and improvements in clinical care, kidney disease due to diabetes remains the most common cause of chronic kidney failure worldwide. In the search for new treatments, recent attentions have turned to drug repurposing opportunities, including study of the histon...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165182/ https://www.ncbi.nlm.nih.gov/pubmed/30189630 http://dx.doi.org/10.3390/ijms19092630 |
_version_ | 1783359776524075008 |
---|---|
author | Hadden, Mitchell J. Advani, Andrew |
author_facet | Hadden, Mitchell J. Advani, Andrew |
author_sort | Hadden, Mitchell J. |
collection | PubMed |
description | Despite recent clinical trial advances and improvements in clinical care, kidney disease due to diabetes remains the most common cause of chronic kidney failure worldwide. In the search for new treatments, recent attentions have turned to drug repurposing opportunities, including study of the histone deacetylase (HDAC) inhibitor class of agents. HDACs are a group of enzymes that remove functional acetyl groups from histone and non-histone proteins and they can affect cellular function through both epigenetic and non-epigenetic means. Over the past decade, several HDAC inhibitors have been adopted into clinical practice, primarily for the treatment of hematological malignancy, whereas other existing therapies (for instance valproate) have been found to have HDAC inhibitory effects. Here we review the current HDAC inhibitors in the clinic and under development; the literature evidence supporting the renoprotective effects of HDAC inhibitors in experimental diabetic kidney disease; and the adverse effect profiles that may prevent existing therapies from entering the clinic for this indication. Whereas recent research efforts have shed light on the fundamental actions of HDACs in the diabetic kidney, whether these efforts will translate into novel therapies for patients will require more specific and better-tolerated therapies. |
format | Online Article Text |
id | pubmed-6165182 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61651822018-10-10 Histone Deacetylase Inhibitors and Diabetic Kidney Disease Hadden, Mitchell J. Advani, Andrew Int J Mol Sci Review Despite recent clinical trial advances and improvements in clinical care, kidney disease due to diabetes remains the most common cause of chronic kidney failure worldwide. In the search for new treatments, recent attentions have turned to drug repurposing opportunities, including study of the histone deacetylase (HDAC) inhibitor class of agents. HDACs are a group of enzymes that remove functional acetyl groups from histone and non-histone proteins and they can affect cellular function through both epigenetic and non-epigenetic means. Over the past decade, several HDAC inhibitors have been adopted into clinical practice, primarily for the treatment of hematological malignancy, whereas other existing therapies (for instance valproate) have been found to have HDAC inhibitory effects. Here we review the current HDAC inhibitors in the clinic and under development; the literature evidence supporting the renoprotective effects of HDAC inhibitors in experimental diabetic kidney disease; and the adverse effect profiles that may prevent existing therapies from entering the clinic for this indication. Whereas recent research efforts have shed light on the fundamental actions of HDACs in the diabetic kidney, whether these efforts will translate into novel therapies for patients will require more specific and better-tolerated therapies. MDPI 2018-09-05 /pmc/articles/PMC6165182/ /pubmed/30189630 http://dx.doi.org/10.3390/ijms19092630 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hadden, Mitchell J. Advani, Andrew Histone Deacetylase Inhibitors and Diabetic Kidney Disease |
title | Histone Deacetylase Inhibitors and Diabetic Kidney Disease |
title_full | Histone Deacetylase Inhibitors and Diabetic Kidney Disease |
title_fullStr | Histone Deacetylase Inhibitors and Diabetic Kidney Disease |
title_full_unstemmed | Histone Deacetylase Inhibitors and Diabetic Kidney Disease |
title_short | Histone Deacetylase Inhibitors and Diabetic Kidney Disease |
title_sort | histone deacetylase inhibitors and diabetic kidney disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165182/ https://www.ncbi.nlm.nih.gov/pubmed/30189630 http://dx.doi.org/10.3390/ijms19092630 |
work_keys_str_mv | AT haddenmitchellj histonedeacetylaseinhibitorsanddiabetickidneydisease AT advaniandrew histonedeacetylaseinhibitorsanddiabetickidneydisease |